Thelansis

 Refractory Acute Myeloid Leukemia (AML) affects about 50% of all patients who achieve remission after initial treatment. With a long-term disease-free survival of only approximately 30 to 40% after standard chemotherapy and a paucity of treatment options besides the standard cytarabine and anthracyclines, disease persistence or recurrence occurs in most patients with AML. Outcomes for patients with relapsed or refractory AML are poor, with overall survival (OS) estimated at no more than 10% at three years. The prognosis for relapsed acute myeloid leukemia (AML) is unfavorable, and managing the disease presents significant challenges. Among patients who achieve complete remission after relapse, allogeneic hematopoietic cell transplantation (allo-HCT) remains the most effective treatment option. Relapse after allo-HCT remains a major obstacle, with a 1-year post-relapse OS of ~20%. Although several therapeutic options are available for relapsed AML after transplantation, only a mino...

 Refractory Acute Myeloid Leukemia (AML) affects about 50% of all patients who achieved remission after initial treatment. With a long-term disease-free survival of only approximately 30 to 40% after standard chemotherapy and a paucity of treatment options besides the standard cytarabine and anthracyclines, disease persistence or recurrence occurs in most patients with AML. Outcomes for patients with relapsed or refractory AML are poor, with overall survival (OS) estimated at no more than 10% at three years. The prognosis of relapsed acute myeloid leukaemia (AML) is poor, and treatment is challenging. While the most potent treatment modality for patients who achieve a complete remission after relapse is still allogeneic haematopoietic cell transplantation (allo-HCT). Relapse after allo-HCT remains a major obstacle with 1-year post-relapse OS of ~20%. Although several therapeutic options are available for relapsed AML after transplantation, only a minority of patients survive long-t...